Compare ARK Genomic Revolution ETF (ARKG) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Visa Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.89, while Visa Inc trades at $355.56 (market cap $663.65B). The key difference: Visa Inc pays a 0.77% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | V | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $362.13 |
52-Week Low | $23.09 | $295.52 |
Market Cap | — | $663.65B |
Volume | — | 10,431,336 |
Enterprise Value | — | $674.24B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Visa (V) trades at $351.21, up 0.64% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $3.31 exceeding the $3.10 forecast. Revenue grew to $40 billion in 2025, and net income margin remains robust at 51.68%. Recent news highlights Visa's push into AI-driven commerce and stablecoin partnerships, positioning it for future growth.
The outlook is positive, with an analyst consensus price target of $395 implying 12% upside. Risks include competitive threats from fintech and regulatory pressures. Institutional ownership trends show increased positions, supporting the bullish sentiment. Visa's strong cash flow and profitability underpin its long-term investment appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
